Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02673606 · ClinicalTrials.gov registry record · Phase 1
Impact of Estrogen on Fear Extinction R61
A Phase 1 study of Fear and Fear; Examination, Phobic, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT02673606 is a Phase 1 study of Fear and Fear; Examination, Phobic that has completed, run by NYU Langone Health. The registered enrollment target is 136 participants, below the 251-participant average among 8 other Fear trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02673606, a Phase 1 study of Fear and Fear; Examination, Phobic, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this project is to examine how estrogen may influence the resting-state connectivity and the extinction-induced activation of the fear extinction network.
Conditions Studied
Interventions
- DRUG Estradiol 2Mg Tablet
- DRUG Estradiol 4Mg Tablet
- DRUG Placebo Pills
Study Locations (1)
New York
- NYU School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2013-01 |
| Est. Completion | 2019-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02673606
The ClinicalTrials.gov registry entry for NCT02673606 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 251-participant average among 8 other Fear trials with a reported enrollment target (46% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Fear appearing as the primary indexed condition, and to 3 interventions - of which Estradiol 2Mg Tablet is the first listed.
NCT02673606 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02673606 about?
NCT02673606 is a clinical study titled "Impact of Estrogen on Fear Extinction R61". The goal of this project is to examine how estrogen may influence the resting-state connectivity and the extinction-induced activation of the fear extinction network.
What is the current status of trial NCT02673606?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2013-01. Estimated completion is 2019-04-15.
What conditions does trial NCT02673606 study?
This clinical trial studies the following conditions: Fear, Fear; Examination, Phobic.
What interventions are being tested in trial NCT02673606?
The interventions under investigation include: Estradiol 2Mg Tablet (DRUG), Estradiol 4Mg Tablet (DRUG), Placebo Pills (DRUG).
Who is sponsoring clinical trial NCT02673606?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02673606 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fear
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Social Support and Reduced Fear Acquisition
RECRUITING · NA
-
Social Support and Enhanced Fear Extinction
RECRUITING · NA
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans
RECRUITING · NA
-
Addressing Anxiety in 2-3-Year-Olds: A Pilot Intervention Study
ACTIVE NOT RECRUITING · NA
-
Effect of rTMS on Anxiety
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.